Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

598.05 +9.78 (+1.66%)
Official Closing Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Are These Biotechs Ready To Launch?
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs. 
Via Benzinga
Pharma Giant Eli Lilly's Shareholder Bonanza: Announces Hefty 15% Dividend Hike For Q1
Eli Lilly and Company (NYSE: LLY) has boosted its quarterly dividend by an impressive 15%, announcing a payout of $1.30 per share  
Via Benzinga
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
These drugs address a rapidly growing market. 
Via The Motley Fool
Challenging the Magnificent 7: 3 Stocks on the Rise
The S&P 500 is performing well thanks largely to the Magnificent 7. Here are three companies whose stocks could soon join the exclusive club. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Pictures Of Lilly
It’s a straight blast higher, day after day, and it has a price/earnings ratio in the triple digits. 
Via Talk Markets
Eli Lilly's Options Frenzy: What You Need to Know
Via Benzinga
What the Options Market Tells Us About Eli Lilly
Via Benzinga
Will There Be A Recession In 2024?
A discussion about what should investors do next year, now that the growth stocks have rebounded. 
Via Talk Markets
Topics Economy
Exposures Economy
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Better Large-Cap Growth Fund: Schwab U.S. Large-Cap Growth or Vanguard Growth Index Fund?
Which of these top-performing growth funds is the better buy? 
Via The Motley Fool
Should You Buy Eli Lilly Stock Now or Wait for a Dip?
Eli Lilly's P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge growth. 
Via The Motley Fool
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge. 
Via The Motley Fool
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
This dividend-paying pharma stock is on a roll. 
Via The Motley Fool
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic 
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news. 
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage 
Via MarketBeat
Exposures Product Safety
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
FDA Grants Second Conditional Approval For Eli Lilly's Rare Blood Cancer Drug
Friday, the FDA approved Eli Lilly and Co's (NYSE: LLY) Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymp 
Via Benzinga
Exposures Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Roche Holding AG (OTC: RHHBY) has agreed to 
Via Benzinga
3 No-Brainer Growth Stocks to Buy in December
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate... 
Via Talk Markets
An Important History Lesson for Gene-Editing Investors
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade. 
Via The Motley Fool
5 Top Stocks to Buy Before 2024
These stocks have room to run -- next year and over the long term. 
Via The Motley Fool
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO). 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.